Global Blood Therapeutics Inc (NASDAQ:GBT) shares traded down 0.6% during mid-day trading on Tuesday . The company traded as low as $32.60 and last traded at $32.81. 14,829 shares traded hands during trading, a decline of 99% from the average session volume of 1,030,456 shares. The stock had previously closed at $33.01.

Several research firms have recently weighed in on GBT. HC Wainwright set a $125.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Thursday, August 23rd. Zacks Investment Research cut shares of Global Blood Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 28th. Cantor Fitzgerald set a $96.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Thursday, August 23rd. BidaskClub upgraded shares of Global Blood Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 8th. Finally, Piper Jaffray Companies began coverage on shares of Global Blood Therapeutics in a report on Monday, August 6th. They issued an “overweight” rating and a $80.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $80.20.

The stock has a market capitalization of $1.90 billion, a PE ratio of -11.96 and a beta of 3.70.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings data on Tuesday, November 6th. The company reported ($0.83) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.85) by $0.02. During the same quarter in the prior year, the business earned ($0.66) earnings per share. As a group, equities research analysts forecast that Global Blood Therapeutics Inc will post -3.37 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc grew its stake in Global Blood Therapeutics by 12.3% during the third quarter. Legal & General Group Plc now owns 18,065 shares of the company’s stock worth $686,000 after buying an additional 1,973 shares in the last quarter. Rehmann Capital Advisory Group acquired a new stake in Global Blood Therapeutics during the third quarter worth about $165,000. Teachers Advisors LLC grew its stake in Global Blood Therapeutics by 0.5% during the third quarter. Teachers Advisors LLC now owns 325,132 shares of the company’s stock worth $12,355,000 after buying an additional 1,588 shares in the last quarter. MetLife Investment Advisors LLC grew its stake in Global Blood Therapeutics by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 35,836 shares of the company’s stock worth $1,362,000 after buying an additional 12,739 shares in the last quarter. Finally, Nexthera Capital LP grew its stake in Global Blood Therapeutics by 35.9% during the third quarter. Nexthera Capital LP now owns 549,231 shares of the company’s stock worth $20,871,000 after buying an additional 145,139 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: This news story was posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2018/11/20/global-blood-therapeutics-gbt-trading-down-0-6.html.

Global Blood Therapeutics Company Profile (NASDAQ:GBT)

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Read More: How to Invest in a Bull Market

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.